Citadel Advisors’s Surmodics SRDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,600
Closed -$110K 14951
2025
Q1
$110K Sell
3,600
-1,000
-22% -$33.7K ﹤0.01% 11329
2024
Q4
$182K Buy
4,600
+3,200
+229% +$124K ﹤0.01% 10598
2024
Q3
$54.3K Buy
1,400
+900
+180% +$36.4K ﹤0.01% 11816
2024
Q2
$21K Buy
500
+300
+150% +$10.2K ﹤0.01% 12592
2024
Q1
$5.87K Buy
200
+100
+100% +$3.19K ﹤0.01% 13720
2023
Q4
$3.63K Sell
100
-300
-75% -$9.83K ﹤0.01% 13572
2023
Q3
$12.8K Sell
400
-2,300
-85% -$78.1K ﹤0.01% 12946
2023
Q2
$84.5K Sell
2,700
-5,800
-68% -$132K ﹤0.01% 11176
2023
Q1
$194K Buy
8,500
+3,300
+63% +$85K ﹤0.01% 10243
2022
Q4
$177K Buy
+5,200
New +$174K ﹤0.01% 10351
2019
Q3
Sell
-5,100
Closed -$220K 9720
2019
Q2
$220K Buy
+5,100
New +$215K ﹤0.01% 8057
2019
Q1
Sell
-13,000
Closed -$614K 9845
2018
Q4
$614K Sell
13,000
-8,400
-39% -$504K ﹤0.01% 6091
2018
Q3
$1.6M Buy
21,400
+16,600
+346% +$1.14M ﹤0.01% 4765
2018
Q2
$265K Buy
+4,800
New +$222K ﹤0.01% 7419
2015
Q4
Sell
-1,300
Closed -$28K 9172
2015
Q3
$28K Sell
1,300
-1,200
-48% -$28.2K ﹤0.01% 7970
2015
Q2
$59K Buy
2,500
+600
+32% +$15.1K ﹤0.01% 7553
2015
Q1
$49K Sell
1,900
-1,500
-44% -$35.7K ﹤0.01% 7395
2014
Q4
$75K Buy
3,400
+2,200
+183% +$46.6K ﹤0.01% 6900
2014
Q3
$22K Sell
1,200
-800
-40% -$16K ﹤0.01% 7361
2014
Q2
$43K Sell
2,000
-800
-29% -$17.1K ﹤0.01% 6858
2014
Q1
$63K Buy
2,800
+200
+8% +$4.88K ﹤0.01% 6576
2013
Q4
$63K Sell
2,600
-1,400
-35% -$33K ﹤0.01% 5911
2013
Q3
$95K Buy
4,000
+3,200
+400% +$68.6K ﹤0.01% 5386
2013
Q2
$16K Buy
+800
New +$20K ﹤0.01% 6124

Other funds holding SRDX

Citadel Advisors's SRDX Position: Q4 2025 in Review

Citadel Advisors sold out of Surmodics (SRDX) in Q4 2025, closing a stake of 365,110 shares — an estimated $10.9M sold.

Citadel Advisors first reported a position in SRDX in Q2 2013 and held it in 42 quarters. The position peaked at $10.9M in Q3 2025. 1 fund tracked by Wall St. Rank holds SRDX as of Q4 2025.

  • Citadel Advisors reported no remaining Surmodics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 365,110 Surmodics shares in Q4 2025, an estimated $10.9M.
  • Citadel Advisors first reported a position in Surmodics in Q2 2013 and held it in 42 quarters.
  • Citadel Advisors's Surmodics position peaked at $10.9M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Surmodics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.